DE60326341D1 - Verfahren zur herstellung von anthranilsäurederivat-hydrat - Google Patents

Verfahren zur herstellung von anthranilsäurederivat-hydrat

Info

Publication number
DE60326341D1
DE60326341D1 DE60326341T DE60326341T DE60326341D1 DE 60326341 D1 DE60326341 D1 DE 60326341D1 DE 60326341 T DE60326341 T DE 60326341T DE 60326341 T DE60326341 T DE 60326341T DE 60326341 D1 DE60326341 D1 DE 60326341D1
Authority
DE
Germany
Prior art keywords
hydrate
acid derivative
anthranilic acid
filtrate
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60326341T
Other languages
German (de)
English (en)
Inventor
David Frank Hayman
Michael Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azatrius Pharmaceuticals Private Ltd Mumbai In
Original Assignee
Xenova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenova Ltd filed Critical Xenova Ltd
Application granted granted Critical
Publication of DE60326341D1 publication Critical patent/DE60326341D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60326341T 2002-05-14 2003-05-13 Verfahren zur herstellung von anthranilsäurederivat-hydrat Expired - Lifetime DE60326341D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37975902P 2002-05-14 2002-05-14
PCT/GB2003/002060 WO2003095447A1 (en) 2002-05-14 2003-05-13 Process for the preparation of a hydrate of an anthranilic acid derivative

Publications (1)

Publication Number Publication Date
DE60326341D1 true DE60326341D1 (de) 2009-04-09

Family

ID=29420557

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60326341T Expired - Lifetime DE60326341D1 (de) 2002-05-14 2003-05-13 Verfahren zur herstellung von anthranilsäurederivat-hydrat

Country Status (11)

Country Link
US (1) US7524861B2 (https=)
EP (1) EP1506188B1 (https=)
JP (1) JP4464814B2 (https=)
KR (1) KR101060971B1 (https=)
CN (1) CN100349888C (https=)
AT (1) ATE423778T1 (https=)
AU (1) AU2003233899B2 (https=)
BR (1) BR0309990A (https=)
CA (1) CA2485430C (https=)
DE (1) DE60326341D1 (https=)
WO (1) WO2003095447A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100557093B1 (ko) 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
RS56037B1 (sr) 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
FR2873585B1 (fr) * 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
EP1979367A2 (en) * 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Quinolin-4-one derivatives as modulators of abc transporters
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 薬学的組成物およびその投与
CA2919522C (en) 2013-07-30 2019-02-26 Gilead Connecticut, Inc. Formulation of syk inhibitors
EA029281B1 (ru) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
CN103804352B (zh) * 2014-01-23 2017-06-13 中国药科大学 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
CN104327046B (zh) * 2014-10-14 2017-11-17 中国药科大学 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用
CN104434947B (zh) * 2014-11-07 2016-11-09 滨州医学院附属医院 一种抗胆管癌的药物组合物及其应用
EP3378858A1 (en) * 2017-03-21 2018-09-26 Bioprojet Tetrahydrate of h3 ligand, its process of preparation and pharmaceutical compositions comprising the same
CA3073871A1 (en) 2017-08-25 2019-02-28 Gilead Sciences, Inc. Polymorphs of syk inhibitors
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式
WO2022076662A1 (en) * 2020-10-07 2022-04-14 Athenex, Inc. Acetamido-phenylbenzamide derivatives and methods of using the same
CN112724124A (zh) * 2021-01-18 2021-04-30 林剑雄 4-羟基喹啉类衍生物及其制备方法和在抗肿瘤药物中的应用
CN117304105A (zh) * 2023-08-18 2023-12-29 中国科学院基础医学与肿瘤研究所(筹) 一种靶向抑制ABCB1(P-gp)的化合物及制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK280864B6 (en) * 1991-01-11 2000-08-14 Laboratoires Glaxo Sa Acridine derivatives, process for their preparation, and pharmaceutical compositions based thereon
GB9717576D0 (en) 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
HUP0001531A3 (en) * 1996-10-18 2000-09-28 Xenova Ltd Slough Anthranilic acid derivatives as multi drug resistance modulators

Also Published As

Publication number Publication date
WO2003095447A1 (en) 2003-11-20
US20050222199A1 (en) 2005-10-06
EP1506188A1 (en) 2005-02-16
US7524861B2 (en) 2009-04-28
AU2003233899B2 (en) 2009-03-12
JP4464814B2 (ja) 2010-05-19
CN1665806A (zh) 2005-09-07
EP1506188B1 (en) 2009-02-25
JP2005538051A (ja) 2005-12-15
AU2003233899A1 (en) 2003-11-11
KR20050009706A (ko) 2005-01-25
KR101060971B1 (ko) 2011-09-01
BR0309990A (pt) 2005-02-22
CA2485430A1 (en) 2003-11-20
CN100349888C (zh) 2007-11-21
ATE423778T1 (de) 2009-03-15
CA2485430C (en) 2011-12-06

Similar Documents

Publication Publication Date Title
DE60326341D1 (de) Verfahren zur herstellung von anthranilsäurederivat-hydrat
CN104936961B (zh) (1s,4s,5s)-4-溴-6-氧杂二环[3.2.1]辛-7-酮的制备方法
US11897843B2 (en) Process for the preparation of enantiomerically enriched 3-aminopiperidine
NO20052912L (no) Metode for fremstilling av krystallinske former for optiske enantiomerer av modafinil
ES2706314T3 (es) Método para la producción de praziquantel y precursores del mismo
ATE299144T1 (de) Verfahren zur herstellung einer pharmazeutisch aktiven verbindung (granisetron)
JP5826371B2 (ja) ペメトレキセド塩の製造方法
JP2010510253A5 (https=)
RU2387656C2 (ru) Способ получения гидробромида галантамина
ATE515496T1 (de) Verfahren zur herstellung von enantiomerenangereicherter indolin-2-carbonsäure
BR112020010618B1 (pt) Método para preparar acetato de salicilamina
JP2002513021A (ja) 1,3−二置換−4−オキソ環式尿素の製造方法
AR127964A1 (es) Sal novedosa de un derivado de 1-sulfonilpirrol, método de preparación de la misma y composición farmacéutica que comprende la misma
ATE325797T1 (de) Verfahren zur herstellung von hochreinem triethylendiamin
DE502005004950D1 (de) Verfahren zur herstellung einer lösung von reinem triethylendiamin (teda)
ATE472523T1 (de) Verbessertes verfahren zur herstellung von rivastigmin
JPH07101937A (ja) フェニルアゾピラゾール系化合物の精製方法
JPH1036327A (ja) 1−(3−メトキシフェニル)エチルアミンの光学活性体の製造方法
JP2009062392A (ja) 環化法
RU2019104860A (ru) Способ разделения солей баклофена
BR112020009568A2 (pt) Método de produção de composto intermediário para síntese de medicamento
JPH03170486A (ja) 新規なオキサゾピロロキノリン化合物
RU2020138321A (ru) Способ получения (4s)-4-(4-циано-2-метоксифенил)-5-этокси-2,8-диметил-1,4-дигидро-1,6-нафтиридин-3-карбоксамида посредством разделения рацемата при помощи диастереомерного сложного эфира винной кислоты
DE60219837D1 (de) Kristalline form von quinapril hydrochlorid und verfahren zu dessen herstellung
JP2003096075A (ja) キノロンカルボン酸誘導体の製法

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: AZATRIUS PHARMACEUTICALS PRIVATE LTD., MUMBAI, IN

8364 No opposition during term of opposition